Patent intelligence · WO
WO 2026109729
COMBINAISON COMPRENANT LE CAPIVASERTIB ET L'ABIRATÉRONE POUR LE TRAITEMENT DU CANCER DE LA PROSTATE MÉTASTATIQUE SENSIBLE AUX HORMONES (MHSPC) DÉFICIENT EN PTEN
COMBINAISON COMPRENANT LE CAPIVASERTIB ET L'ABIRATÉRONE POUR LE TRAITEMENT DU CANCER DE LA PROSTATE MÉTASTATIQUE SENSIBLE AUX HORMONES (MHSP…
Patent details — WO 2026109729
- Jurisdiction
- WO
- Status
- granted
- Grant date
- May 28, 2026
- Expiration
- May 23, 2046
- Applicant
- ASTRAZENECA AB [SE]
- CPC classes
- A61K 31/ 58 A I, A61K 31/ 519 A I, A61K 31/ 573 A I, A61K/31519
Quick answer
WO 2026109729 (COMBINAISON COMPRENANT LE CAPIVASERTIB ET L'ABIRATÉRONE POUR LE TRAITEMENT DU CANCER DE LA PROSTATE MÉTASTATIQUE SENSIBLE AUX HORMONES (MHSPC) DÉFICIENT EN PTEN) is held by ASTRAZENECA AB [SE]. Status: granted. Granted May 28, 2026. Expires May 23, 2046 (20 years remaining) — relevant for patent-cliff and LOE planning.
Key facts
- Applicant
- ASTRAZENECA AB [SE]
- Grant date
- Expiration
- Claims
- —
- CPC classes
- A61K 31/ 58 A I, A61K 31/ 519 A I, A61K 31/ 573 A I, A61K/31519, A61K/31573, A61K/3158
More from ASTRAZENECA AB [SE]
Related pharmaceutical patents in our USPTO index.
Related coverage
FDA approves capivasertib plus abiraterone and prednisone in PTEN-deficient mHSPC
The FDA approved capivasertib plus abiraterone and prednisone for adult patients with PTEN-deficient metastatic androgen pathway modulation-naïve or sensitive prostate cancer. The move creates a new catalyst for AstraZeneca’s Truqap and adds a biomarker-defined prostate cancer use to track.
Truqap gains US approval in PTEN-deficient metastatic prostate cancer
AstraZeneca’s Truqap (capivasertib) has been approved in the US with abiraterone and prednisone for PTEN-deficient metastatic prostate cancer. The move creates a first-in-class targeted option and a new catalyst to watch for BD teams, investors, and analysts.
Frequently asked questions
What is US patent 2026109729?
WO 2026109729 (COMBINAISON COMPRENANT LE CAPIVASERTIB ET L'ABIRATÉRONE POUR LE TRAITEMENT DU CANCER DE LA PROSTATE MÉTASTATIQUE SENSIBLE AUX HORMONES (MHSPC) DÉFICIENT EN PTEN) is held by ASTRAZENECA AB [SE]. Status: granted. Granted May 28, 2026. Expires May 23, 2046 (20 years remaining) — relevant for patent-cliff and LOE planning.
Who owns WO 2026109729?
ASTRAZENECA AB [SE] is listed as the applicant in USPTO PatentsView records indexed by NovaPharmaNews. We track 2 pharmaceutical patents for this assignee.
When does WO 2026109729 expire?
Our index shows an expiration date of May 23, 2046 (20 years from today). Confirm material dates against USPTO, FDA Orange Book, or qualified counsel before contractual decisions.